文献速递糖尿病肥胖与代谢综合征

司美格鲁肽治疗肥胖相关射血分数保留的心力衰竭合并2型糖尿病:基线HbA1c水平的预设分析

Semaglutide in obesity-related heart failure with preserved ejection fraction and type 2 diabetes across baseline HbA1c levels (STEP-HFpEF DM): a prespecified analysis of heart failure and metabolic outcomes from a randomised, placebo-controlled trial.
PubMed 文献 · Lancet Diabetes Endocrinol · 2025-01-20

STEP-HFpEF DM试验的预设分析,纳入616例肥胖相关HFpEF合并2型糖尿病患者,按基线HbA1c分低、中、高三组,评估司美格鲁肽2.4mg与安慰剂相比对心衰症状、体重及低血糖的影响。结果显示司美格鲁肽改善KCCQ-CSS和减轻体重,且不依赖基线HbA1c水平,低血糖发生率低于安慰剂。

要点

  • 司美格鲁肽2.4mg改善HFpEF合并2型糖尿病患者的KCCQ-CSS和体重,各HbA1c亚组一致。
  • 低血糖事件司美格鲁肽组30例(10%)vs 安慰剂组21例(7%)。
  • 疗效与基线HbA1c无显著交互作用(KCCQ-CSS p交互=0.64,体重p交互=0.22)。

核心结论

  • 司美格鲁肽2.4mg改善肥胖相关HFpEF合并2型糖尿病患者的心衰相关症状和体力限制,并减轻体重,且不依赖基线HbA1c水平。
  • 司美格鲁肽组低血糖发生率低于安慰剂组,尽管基线HbA1c控制良好且广泛使用降糖药物。

研究设计与样本

  • STEP-HFpEF DM为双盲、随机、安慰剂对照试验,在亚洲、欧洲、北美和南美16个国家的108个临床研究中心进行。
  • 纳入年龄≥18岁、 documented HFpEF(左心室射血分数≥45%)、2型糖尿病和肥胖(BMI≥30 kg/m2)的个体。
  • 参与者按1:1随机分配,采用区组大小为4的交互式网络应答系统,按基线BMI(<35 kg/m2 vs ≥35 kg/m2)分层,接受司美格鲁肽2.4mg或安慰剂皮下注射。
  • 共纳入616例参与者,按基线HbA1c分类:低(<6.5%;<48 mmol/mol)227例(司美格鲁肽112例,安慰剂115例),中(6.5%至<7.5%;48至<58 mmol/mol)226例(司美格鲁肽124例,安慰剂102例),高(≥7.5%;≥58 mmol/mol)163例(司美格鲁肽74例,安慰剂89例)。
  • 双主要终点为从基线至52周KCCQ-CSS和体重百分比变化,在意向治疗人群中评估;低血糖事件在至少接受一剂研究药物的随机参与者中分析。

主要发现

  • 低基线HbA1c组KCCQ-CSS变化:司美格鲁肽12.4分(95%CI 8.8至16.0)vs 安慰剂5.7分(2.1至9.2),平均差异6.7分(1.6至11.8)。
  • 中基线HbA1c组KCCQ-CSS变化:司美格鲁肽14.5分(11.0至17.9)vs 安慰剂8.5分(4.8至12.2),平均差异6.0分(0.9至11.1)。
  • 高基线HbA1c组KCCQ-CSS变化:司美格鲁肽14.5分(10.0至19.0)vs 安慰剂4.8分(0.7至8.9),平均差异9.6分(3.5至15.7);p交互=0.64,p趋势=0.46。
  • 体重百分比变化:低基线HbA1c组司美格鲁肽-10.8%(-12.1至-9.5)vs 安慰剂-3.3%(-4.6至-2.0),平均差异-7.5%(-9.4至-5.6);中基线HbA1c组-9.6%(-10.8至-8.3)vs -3.3%(-4.7至-1.9),平均差异-6.3%(-8.2至-4.4);高基线HbA1c组-8.6%(-10.2至-7.0)vs -3.6%(-5.2至-2.1),平均差异-5.0%(-7.2至-2.7);p交互=0.22,p趋势=0.083。
  • 低血糖事件:司美格鲁肽组310例中30例(10%)发生(70次事件;22.9次/100人年),安慰剂组306例中21例(7%)发生(90次事件;29.5次/100人年)。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: About half of patients with heart failure with mildly reduced or preserved ejection fraction (HFpEF) have type 2 diabetes. In the STEP-HFpEF DM trial of adults with obesity-related HFpEF and type 2 diabetes, subcutaneous once weekly semaglutide 2·4 mg conferred improvements in heart failure-related symptoms and physical limitations, bodyweight, and other heart failure outcomes. We aimed to determine whether these effects of semaglutide differ according to baseline HbA1c. METHODS: STEP-HFpEF DM, a double-blind, randomised, placebo-controlled trial conducted at 108 clinical research sites across 16 countries in Asia, Europe, and North and South America, included individuals aged 18 years or older with documented HFpEF (left ventricular ejection fraction ≥45%), type 2 diabetes, and obesity (BMI ≥30 kg/m2). Participants were randomly assigned (1:1), with a block size of four within each stratum using an interactive web response system, stratified by baseline BMI (<35 kg/m2vs ≥35 kg/m2), to receive either semaglutide 2·4 mg or placebo subcutaneously. The effects of semaglutide versus placebo on the efficacy endpoints were evaluated by HbA1c categories at baseline: low (<6·5%; <48 mmol/mol), medium (6·5% to <7·5%; 48 mmol/mol to <58 mmol/mol), and high (≥7·5%; ≥58 mmol/mol). The dual primary endpoints were change in the Kansas City Cardiomyopathy Questionnaire Clinical Summary Score (KCCQ-CSS) and bodyweight percentage from baseline to 52 weeks and were assessed in all randomly assigned participants by intention to treat. Hypoglycaemia events were also analysed to assess safety in all randomly assigned participants who received at least one dose of study drug. This trial is registered with ClinicalTrials.gov, NCT04916470. FINDINGS: Between June 27, 2021 and Sept 2, 2022, 616 participants were enrolled and randomly assigned (mean age 68·4 years [SD 8·9]; 273 [44%] were female, 343 [56%] were male, and 519 [84%] were White). The low baseline HbA1c group included 227 participants (112 assigned to semaglutide and 115 to placebo), the medium baseline HbA1c group included 226 participants (124 assigned to semaglutide and 102 to placebo), and the high baseline HbA1c group included 163 participants (74 assigned to semaglutide and 89 to placebo). The median duration of follow-up in the overall trial was 401 days (IQR 400-405). The change in KCCQ-CSS from baseline to 52 weeks was 12·4 points (95% CI 8·8 to 16·0) with semaglutide versus 5·7 points (2·1 to 9·2) with placebo (mean difference 6·7 points [1·6 to 11·8]) in the low baseline HbA1c group, 14·5 points (11·0 to 17·9) versus 8·5 points (4·8 to 12·2; 6·0 points [0·9 to 11·1]) in the medium baseline HbA1c group, and 14·5 points (10·0 to 19·0) versus 4·8 points (0·7 to 8·9; 9·6 points [3·5 to 15·7]) in the high baseline HbA1c group (pinteraction=0·64; ptrend=0·46). The change in bodyweight percentage from baseline to 52 weeks was -10·8 (95% CI -12·1 to -9·5) with semaglutide versus -3·3% (-4·6 to -2·0) with placebo (mean difference -7·5% [-9·4 to -5·6]) in the low baseline HbA1c group, -9·6% (-10·8 to -8·3) versus -3·3% (-4·7 to -1·9; -6·3 [-8·2 to -4·4]) in the medium baseline HbA1c group, and -8·6% (-10·2 to -7·0) versus -3·6% (-5·2 to -2·1; -5·0 [-7·2 to -2·7]) in the high baseline HbA1c group (pinteraction=0·22; ptrend=0·083). Hypoglycaemia events occurred in 30 (10%) of 310 participants (70 events; 22·9 events per 100 person-years) in the semaglutide group compared with 21 (7%) of 306 participants in the placebo group (90 events; 29·5 events per 100 person-years). INTERPRETATION: Semaglutide 2·4 mg improved heart failure-related symptoms and physical limitations, and reduced bodyweight in patients with obesity-related HFpEF and type 2 diabetes, all independently of baseline HbA1c, and resulted in lower rates of hypoglycaemia than placebo, despite a well controlled baseline HbA1c and broad use of concomitant glucose-lowering medications. FUNDING: Novo Nordisk.

来源:Lancet Diabetes Endocrinol,查看原文。版权归原作者所有。

引用

  1. Davies MJ, van der Meer P, Verma S, et al. Semaglutide in obesity-related heart failure with preserved ejection fraction and type 2 diabetes across baseline HbA1c levels (STEP-HFpEF DM): a prespecified analysis of heart failure and metabolic outcomes from a randomised, placebo-controlled trial. Lancet Diabetes Endocrinol. 2025. PMID: 39848268. doi:10.1016/S2213-8587(24)00304-8

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。